CAMBIUM BIO LIMITED — Director's Dealing 2022

Jun 9, 2022

ASX Announcement 10 June 2022

==> picture [160 x 33] intentionally omitted <==

Regeneus CEO cements support with 3.8 million share purchase

Highlights

• Regeneus’ Chief Executive Officer, Karolis Rosickas, purchases 3,836,366 RGS shares for a total consideration of A$153,455.

• Share purchase follows strong clinical progress to date and the securing of A$4 million non-dilutive funding in April this year

• This funding positions Regeneus strongly financially with no further capital requirements to progress its current operations

• Cements Karolis’ and the RGS leadership team’s commitment to the Company’s growth as it progresses through its clinical pipeline towards commercialisation of its two leading stem cell technologies, Progenza™ and Sygenus

Regeneus Ltd (ASX: RGS) ( Regeneus or the Company ), a clinical-stage regenerative medicine company, is pleased to announce its Chief Executive Officer, Karolis Rosickas, has purchased 3,836,366 fully paid ordinary shares off market at the volume weighted average price (VWAP) of $0.04 per share, equating A$153,454.64. These shares were purchased in accordance with the Company’s Securities Trading Policy. The Company confirms that at the time of this purchase Karolis was not in possession of any market sensitive information not otherwise disclosed to the market.

Karolis Rosickas commented: “I have a firm conviction in the value of Regeneus’ differentiated technology and its clinical pipeline. Cell and gene therapies are becoming a more prominent modality in the pharmaceuticals industry, and Regeneus is at the forefront in developing and commercialising novel and highly efficacious treatments for patients.”

Karolis’ share purchase follows strong traction delivered to date with regards to:

• The Company’s ongoing partnership discussions in South Korea, China and the USA;

• A collaborative relationship with Kyocera Corporation in Japan to establish Progenza manufacturing capabilities and the launch a pivotal clinical trial on osteoarthritis of the knee to obtain commercial marketing approval; and,

• Ongoing Sygenus co-development with the Australian Department of Defence

This also follows the announcement that Regeneus has secured non-dilutive funding of A$4 million from Paddington Street Finance Pty Ltd against Kyocera's upcoming US$3 million milestone payment which is expected in Q2 CY2023 (Ref announcement: 29 April 2022).

2 Paddington Street, Paddington, NSW 2021 Ph: 1300 995 098 • www.regeneus.com.au • ABN 13 127 035 358

==> picture [160 x 33] intentionally omitted <==

This ensures the Company remains in a highly capital efficient position and does not require any further funding to maintain and progress its existing operations.

This investment demonstrates the unwavering support and conviction of Regeneus’ leadership team as it continues to deliver material progress of its clinical pipeline towards commercialisation of its two leading stem cell technologies, Progenza™ and Sygenus.

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza[TM] and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

Investor and Media Contact

This announcement was authorised by Hannah Howlett, WE Communications the Board of Directors of Regeneus Ltd T: 04 5064 8064 E: hhowlett@we-worldwide.com

2 Paddington Street, Paddington, NSW 2021 Ph: 1300 995 098 • www.regeneus.com.au • ABN 13 127 035 358